The Technical AnalystExchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Patrys Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0080
America/New_York / 3 mai 2024 @ 01:05
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 16.46 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Feb 22, 2024 |
| SharesOutstanding: | 2 057.45 mill |
| Avg Daily Volume: | 1.121 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 1.258 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 38.27 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0070 - 0.0090 ( +/- 12.50%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0080 (0.00% ) |
| Volume | 1.167 mill |
| Avg. Vol. | 1.121 mill |
| % of Avg. Vol | 104.15 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PAB.AX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PAB.AX
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. The company was incorporated in 2006 and is based in Melbourne, Australia.